Silence Therapeutics PLC (SLN) - Stock & Dividends

Silence Therapeutics plc is a biotechnology company that focuses on developing innovative treatments for various diseases by harnessing the power of short interfering ribonucleic acid (siRNA). This cutting-edge technology allows the company to inhibit the expression of specific genes, providing a potential solution for a range of debilitating conditions.

The company's proprietary mRNAi GalNAc Oligonucleotide Discovery platform is a game-changer in the field of gene therapy. By precision-engineering product candidates, Silence Therapeutics can target specific disease-associated genes in the liver, offering new hope for patients suffering from rare and debilitating diseases.

Silence Therapeutics has a robust pipeline of promising candidates, including Zerlasiran (SLN360), which is currently in phase 2 clinical trials for cardiovascular disease associated with elevated lipoprotein(a). Another notable candidate is Divesiran (SLN124), an siRNA molecule being developed to treat genetic hematological conditions, including polycythemia vera.

In addition to its internal development programs, Silence Therapeutics has established strategic collaborations with leading pharmaceutical companies, including AstraZeneca PLC, Hansoh Pharmaceutical Group Company Limited, and Mallinckrodt Pharma IP Trading DAC. These partnerships aim to accelerate the discovery, development, and commercialization of siRNA therapeutics for a range of diseases, including cardiovascular, renal, metabolic, and respiratory diseases.

With a rich history dating back to 1994, Silence Therapeutics plc has undergone significant transformations, including a name change from SR Pharma plc in 2007. Today, the company is headquartered in London, United Kingdom, and continues to push the boundaries of gene therapy and RNA interference technology.

For more information on Silence Therapeutics plc, please visit their website at https://www.silence-therapeutics.com.